Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04063488 · ClinicalTrials.gov registry record
The Effects of Metreleptin in Congenital Leptin Deficiency
A clinical trial, sponsored by Northwestern University.
- Completed
- Registry status
- 2
- Enrollment target
NCT04063488: Completed study, sponsored by Northwestern University.
NCT04063488 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04063488 has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study has been designed to 1) provide access to metreleptin to the only two individuals in the US known to have congenital leptin deficiency (CLD) and 2) explore a variety of unanswered questions about leptin physiology in general and metreleptin therapy in CLD specifically. The primary study endpoints include the following measures: body composition, measures of hepatic steatosis, measures of insulin sensitivity, and measures of sleep architecture. Secondary study endpoints include assessment of clock gene expression, body temperature, thyroid function, gonadal function, cognitive function, eating behavior, physical activity, mood, quality of life, and body image.
Primary Outcome
ultrasound elastography with dispersion imaging
Interventions
- DRUG Metreleptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-06-20 |
| Est. Completion | 2021-08-13 |
What the finished NCT04063488 record still lists
NCT04063488 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Metreleptin is the first listed.
NCT04063488 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04063488 about?
NCT04063488 is a clinical study titled "The Effects of Metreleptin in Congenital Leptin Deficiency". This study has been designed to 1) provide access to metreleptin to the only two individuals in the US known to have congenital leptin deficiency (CLD) and 2) explore a variety of unanswered questions about leptin physiology in general and metreleptin therapy in CLD specifically. The primary study ...
What is the current status of trial NCT04063488?
This trial is currently completed. The enrollment target is 2 participants. The study started on 2019-06-20. Estimated completion is 2021-08-13.
What interventions are being tested in trial NCT04063488?
The interventions under investigation include: Metreleptin (DRUG).
Who is sponsoring clinical trial NCT04063488?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI